Welcome to our dedicated page for Nutex Health news (Ticker: NUTX), a resource for investors and traders seeking the latest updates and insights on Nutex Health stock.
Nutex Health Inc. operates as a physician-led healthcare services and operations company with a Hospital Division and a Population Health Management Division. Its hospital operations own, develop and operate micro-hospitals, specialty hospitals and hospital outpatient departments, while the population health business owns provider networks such as independent physician associations and provides management and administrative support through a management services organization.
Company news commonly covers quarterly and annual financial results, hospital openings and reopenings, expansion of facility operations across states, risk-bearing physician network activity, real estate-backed hospital development, earnings calls, healthcare conference participation and common stock repurchase authorizations.
Nutex Health (NASDAQ: NUTX) reported strong results for the three and nine months ended September 30, 2025, driven by the hospital division and arbitration recoveries. Nine‑month revenue was $723.6M, up 225.5% versus 2024, with hospital revenue of $700.5M (up 251.4%). Net income attributable to Nutex Health was $59.0M for nine months versus a $9.5M loss in 2024. EBITDA was $142.9M and Adjusted EBITDA was $243.0M for nine months. Cash and cash equivalents totaled $166.0M and net cash from operating activities was $177.7M for the nine months. The company noted substantial stock‑based compensation of $119.6M and significant reliance on IDR arbitration recoveries (≈66% of hospital revenue for nine months).
Nutex Health (NASDAQ: NUTX) reported strong first-half 2025 results: total revenue $455.8M versus $143.5M (+217.5%), net income attributable $3.5M vs a $0.7M loss, and diluted EPS $0.55. Adjusted EBITDA $144.4M (vs $6.4M), and EBITDA $51.1M. Cash balance was a record $96.7M and net cash from operations was $78.2M. Hospital division visits reached 93,842 (+15.5% YTD). The board authorized an opportunistic $25.0M share repurchase program on August 14, 2025. Total stock-based compensation was $106.4M for H1 2025, primarily for under-construction and ramping hospitals. Total assets were $841.0M as of June 30, 2025.
NUTEX HEALTH (NASDAQ: NUTX) reported restated Q1 2025 results for the quarter ended March 31, 2025, including a 214.0% increase in total revenue to $211.8M and net income attributable to Nutex of $21.2M versus a $0.4M loss in Q1 2024. EBITDA was $51.5M and Adjusted EBITDA was $72.8M. The company recorded $27.6M of stock-based compensation (≈99% related to under-construction and ramping hospitals).
The restatement corrected non-cash classifications (stock-based compensation reclassified from equity to liabilities, related-party payables reclassified to equity, $2.9M moved to short-term investments, and accrued income tax expense increased $2.4M). Total liabilities rose by $19.6M (4.0%), total equity declined $19.6M (7.1%), and net income for the period increased by $6.6M (14.9%) on the restated basis. Cash and cash equivalents were $84.7M and net cash from operating activities was $51.0M.
NUTEX HEALTH (NASDAQ: NUTX) reported restated full-year and Q4 2024 results on Nov 18, 2025 reflecting non-cash reclassifications and immaterial net-income impact.
Key 2024 metrics: total revenue $479.9M (+93.8% vs 2023); net income attributable $52.1M vs loss $45.8M in 2023; diluted EPS $9.69; EBITDA $98.8M; Adjusted EBITDA $124.1M. Q4 revenue $257.6M (+269.8% YoY); Q4 net income $61.6M.
Restatement adjustments reclassified $16.4M of stock‑based compensation to liabilities, moved $3.5M related‑party payables to equity, shifted $2.9M to short‑term investments, and increased accrued tax by $0.5M; total liabilities rose $13.4M (2.9%).
NUTEX HEALTH (NASDAQ: NUTX) appointed Wesley Bamburg as Chief Operating Officer, effective October 13, 2025. Bamburg brings 20 years of Fortune 500 healthcare experience and prior COO roles at HCA Houston Healthcare Medical Center (2019–2024) and HCA Houston Healthcare North Cypress (since July 2024).
The company said Bamburg's background in operations, payor contracting, integrated network management, and physician relations will support Nutex Health's physician-led micro hospital and outpatient expansion across 11 states.
Nutex Health (NASDAQ: NUTX) reported preliminary Q3 2025 operational metrics showing patient volume up 11.1% year‑over‑year (46,293 visits vs. 41,668) and a cash collections increase of 258.8% in Q3 2025 ($235,003k vs. $65,501k). Year‑to‑date patient visits rose 14.0% and YTD cash collections increased 176.9%. Management labels these figures as preliminary estimates subject to final accounting adjustments.
The company disclosed an ongoing restatement related to accounting for earn‑out obligations from a 2022 merger, leading to previously issued statements being unreliable, a Nasdaq non‑compliance notice, and a Nasdaq‑granted exception to file the delinquent Form 10‑Q for June 30, 2025 by December 12, 2025. The Q3 2025 Form 10‑Q will be filed after completing the restatement and related filings.
Nutex Health (NASDAQ: NUTX) announced it earned a record‑breaking 20 awards and honors in the third quarter of 2025, the most in company history, the PR states.
The awards span its network of 24 micro hospitals and HOPDs across 11 states and include community‑voted recognitions for emergency care, hospitals, pediatric services, workplace, CIHQ accreditation at multiple facilities, and a corporate Horizon Award for patient financial experience.
Nutex Health (NASDAQ: NUTX), a physician-led healthcare system operating 24 micro hospitals across 11 states, has appointed Wesley Bamburg as its new Chief Operating Officer, effective October 13, 2025. Bamburg brings 20 years of Fortune 500 healthcare experience, most recently serving as COO at HCA Houston Healthcare North Cypress.
Bamburg's extensive background includes leadership roles in healthcare operations, payor contracting, and physician relations. He holds a BS in Healthcare Administration and an MBA, and is a Fellow of the American College of Healthcare Executives. The appointment strengthens Nutex Health's leadership team as it continues expanding its innovative, patient-centric healthcare delivery model.
[ "Appointment of seasoned healthcare executive with 20 years of Fortune 500 experience", "New COO brings extensive experience in payor contracting and physician relations", "Strong educational background and professional credentials (FACHE certification)", "Previous leadership experience at major healthcare organization (HCA Healthcare)" ]Nutex Health (NASDAQ: NUTX), a healthcare system with 24 micro hospitals across 11 states, announced significant financial restatements and preliminary Q2 2025 results. The company must restate its Q1 2025 and FY 2024/2023 financial statements due to non-cash classification changes related to hospital construction obligations.
Despite these accounting adjustments, Nutex reported strong Q2 2025 performance with revenue increasing 220.7% to $244.0 million and record quarterly cash collections of $175 million. The company achieved an Adjusted EBITDA of $71.6 million, up from $6.8 million in Q2 2024.
However, Nutex received a Nasdaq delinquency notice for delayed Q2 2025 filing and must submit a compliance plan by October 20, 2025, to avoid potential delisting risks.
Nutex Health (NASDAQ: NUTX), a physician-led healthcare system with 24 micro hospitals across 11 states, announced three significant updates: preliminary Q2 2025 results, a Form 10-Q filing delay, and a $25 million stock repurchase program.
The company reported strong Q2 2025 performance with revenue of $244.0 million, up 220.7% year-over-year, and gross profit of $124.9 million (51.2% margin). Total hospital visits increased by 10.6% to 45,573. For H1 2025, revenue reached $455.8 million, up 217.5%, with gross profit of $243.3 million.
The Form 10-Q filing delay is due to non-cash accounting adjustments related to stock-based compensation for under-construction hospitals. The company expects to file within the five-day grace period and confirms these adjustments won't affect revenue, gross profit, or operations.